Among treatment-naive adults living with HIV, CD4 to CD8 ratios do not differ significantly between those on dolutegravir ...
A new injectable solution that self-assembles into a gel under the right conditions could help manage HIV unlike any currently available methods, researchers have found. The gel releases a steady dose ...
Wesley Sundquist, PhD, Samuels Professor and chair of biochemistry at the University of Utah, laid the foundation for the development of a highly effective, long-lasting prophylactic against HIV, ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...
Long-acting injectable antiretroviral therapy improves treatment outcomes in individuals with HIV type 1 (HIV 1) who face adherence challenges, thereby addressing a persistent barrier in routine ...
A Q&A With Shauna Applin, ARNP. AJMC: Despite substantial therapeutic advances since the 1980s, the US is not on pace to achieve the goals of the Ending the HIV Epidemic (EHE) public health initiative ...
In an article published in The Lancet HIV, authors including Distinguished Professor Denis Nash and Professor Constantin Yiannoutsos aim to provide the most comprehensive estimates of pediatric ...
Gilead's expansion beyond HIV therapies will surprise many investors.
HIV treatment has delivered life-altering advantages. Antiretroviral therapy has led to reduced mortality and improved life expectancy for people living with HIV. Nearly 41 million people were living ...
HIV patients in Ghana have raised urgent concerns about an antiretroviral medicine shortage, warning of serious health risks ...
In the densely-populated poor neighbourhoods clustered around Valika Hospital, a quiet crisis is unfolding - one that has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results